Volume 95 Issue 12 | p. 13 | Concentrates
Issue Date: March 20, 2017

Intrexon reorganizes its pharma businesses

Department: Business
Keywords: synthetic biology, gene therapy, Intrexon

As part of a review of its health-related businesses, the synthetic biology company Intrexon has consolidated all its health care assets and put them in a new subsidiary called Precigen. Through collaborations, joint ventures, and the start-up Xogenex, Intrexon’s synthetic biology technology is used in multiple gene- and cell-therapy candidates. Three clinical trials are under way, and up to 10 more could begin this year, the firm says. Separately, Intrexon President Geno Germano, who was . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society